Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05057195
Other study ID # SARCBT-2021-7-11
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 10, 2022
Est. completion date December 2025

Study information

Verified date March 2024
Source Blokhin's Russian Cancer Research Center
Contact Denis Burov, PhD
Phone +79265585000
Email denisburov@yandex.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intraoperatively, in the bed of the removed tumor, a surgical mesh is sutured onto which the intrastats are fixed. On days 2-3, topometric preparation is carried out, the choice of the amount of irradiation, the calculation of the program. On the 4-5th day after the operation, a course of intra-tissue radiation therapy begins in a single dose of 3 to 5 Gy in 10 fractions 2 times a day with an interval between fractions of 6 hours, the planned total dose is from 30 to 50 Gy. (from 40 to 70 IGy). Follow-up examination after 4 weeks and then every 3 months for 24 months


Description:

1 day before the operation, taking blood tests: general blood test with counting the leukocyte formula and the number of platelets; biochemical blood test with the determination of indicators of liver and kidney function (including electrolytes); coagulogram; performing surgical treatment with urgent histological examination of the edge of the tumor; intraoperatively, in the bed of the removed tumor, a surgical mesh is sutured onto which the intrastats are fixed with the fixation of the outlet ends on the skin with the help of buttons. 1 day after the operation, taking blood tests: a general blood test with the calculation of the leukocyte formula and the number of platelets; biochemical blood test with the determination of indicators of liver and kidney function (including electrolytes); coagulogram. On the 2-3rd day after the surgical treatment, topometric preparation, the choice of the amount of radiation, and the calculation of the program are carried out. On the 4-5th day after the operation, a course of interstitial radiation therapy begins in a single dose of 3 to 5 Gy in 10 fractions 2 times a day with an interval between fractions of 6 hours, the planned total dose is from 30 to 50 Gy, which is equivalent to 40 to 70 IGy (isogrey). On the 6th day, removal of intrastats, on the 7th day after the operation, ultrasound of the wound and n / c vessels; assessment of the nature of wound healing. On the 10th day, discharge from the hospital.


Recruitment information / eligibility

Status Recruiting
Enrollment 78
Est. completion date December 2025
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - C49.1 Malignant neoplasm of the connective and soft tissues of the upper limb, including the shoulder girdle - C49.2 Malignant neoplasm of the connective and soft tissues of the lower limb, including the hip region - Tumor size 7 cm or less - For malignant tumors: Grade 2-3 - Locally advanced soft tissue sarcomas - Absence of regional metastases - Tumor recurrence Exclusion Criteria: - Children, women during pregnancy, childbirth, women during breastfeeding. - Military personnel, with the exception of contract military personnel. - Persons with mental disorders. - Persons detained, taken into custody, serving a sentence in the form of restriction of freedom, arrest, imprisonment or administrative arrest. - The age of patients is under 18 years old - Histologically confirmed diagnosis of GIST, Kaposi's sarcoma, alveolar, clear cell sarcoma, chondrosarcoma, paraossal osteosarcoma - Inoperable tumor - A tumor with decay or with the threat of decay - The presence of damage to the skin in the affected area - The presence of a second malignant tumor - Having an active or chronic fungal / bacterial / viral infection - Uncontrolled chronic diseases of the liver, kidneys in the acute stage - Superficial tumor (within the skin) - The use of a reconstructive plastic component using a displaced musculocutaneous flap - The use of vascular prosthetics - The removed tumor bed is more than 7 cm - The presence of a tumor growing into the bone - The presence of blood vessels and nerves in the removed tumor bed - Presence of metastases - Surgical intervention using transplanted skin

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Interstitial radiation therapy
From 30 to 50 Gy,
Postoperative external beam therapy
50 Gy and locally on the tumor bed up to 10-26 Gy, depending on the status of the resection margin

Locations

Country Name City State
Russian Federation Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" ?f the Ministry of Health of the Russian Federation Moscow

Sponsors (1)

Lead Sponsor Collaborator
Blokhin's Russian Cancer Research Center

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease-free survival Time after treatment during which no sign of cancer is found 24 months
Secondary Comparison of hospitalization rate Time after surgery till the end of hospitalization 30 days
Secondary Comparison of safety assessment Adverse Event Assessment and Serious Adverse Event Assessment according to CTCAE 5.0 24 months
Secondary Comparison of performance status according Karnofsky scale Improvement on the Karnofsky scale by 10-30 points 24 months
Secondary Comparison of pain relief according Visual Analogue Scale Improvement on the Visual Analogue Scale by 3-5 points 24 months
Secondary Comparison of pain relief according Whatkins scale Improvement on the Whatkins scale by 1-2 points 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04457258 - 68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma Early Phase 1
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Completed NCT04474678 - Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!") N/A
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Recruiting NCT04535713 - GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma Phase 2
Completed NCT03521531 - Burden and Medical Care of Sarcoma in Germany
Completed NCT02496520 - Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults Phase 1/Phase 2
Terminated NCT02054104 - Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum Phase 1/Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT04052334 - Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Phase 1
Completed NCT01593748 - A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase 2
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Completed NCT01879085 - Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Phase 1/Phase 2
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Completed NCT01209598 - PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Phase 2
Completed NCT04553471 - Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers N/A
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2